Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol in Active Rheumatoid Arthritis
NCT06108518Phase 1Not yet recruiting
- Sponsor
- Tanta University
- Start
- Jun 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of carvedilol in rheumatoid arthritis (RA) (2 arms), sponsored by Tanta University. Primary endpoints: Disease Activity Score-28 with C-Reactive Protein at 12 weeks and Multidimensional Health Assessment Questionnaire at 12 weeks. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
carvedilol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06108518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06108518.